The Economics of Improved Cancer Survival Rates: Better Outcomes, Higher Costs

Carin A Uyl-de Groot; Saskia de Groot; Adri Steenhoek


Expert Rev Pharmacoeconomics Outcomes Res. 2010;10(3):283-292. 

In This Article

Five-year View

New genetic tests and biomarkers may help to identify subtypes of patients who will respond to new cancer drugs. Further research is needed to study the effectiveness of these drugs, especially in areas such as genetic markers, chemotherapy regimens, health-related quality of life and patient views on survival advantages versus treatment disadvantages. The impact of new diagnostic tests and drugs for other cancer types needs to be further investigated to identify which, if any, other patients are likely to benefit from them. This will have a positive impact on the mortality rates, but also on the burden to patients and society.